{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T10:18:10Z","timestamp":1787998690546,"version":"build-2784847793"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T00:00:00Z","timestamp":1667865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T00:00:00Z","timestamp":1667865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Intramural Research Program, National Institutes of Health, National Cancer Institute"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1245\/s10434-022-12761-0","type":"journal-article","created":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T22:03:03Z","timestamp":1667944983000},"page":"1852-1860","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Cytoreduction and HIPEC for Gastric Carcinomatosis: Multi-institutional Analysis of Two Phase II Clinical Trials"],"prefix":"10.1245","volume":"30","author":[{"given":"Benjamin L.","family":"Green","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisa N.","family":"Blumenthaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren A.","family":"Gamble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Blakely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian D.","family":"Badgwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6334-6936","authenticated-orcid":false,"given":"Jeremy L.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,8]]},"reference":[{"issue":"6","key":"12761_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"12761_CR2","first-page":"26","volume":"14","author":"P Rawla","year":"2019","unstructured":"Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. Prz Gastroenterol. 2019;14(1):26\u201338.","journal-title":"Prz Gastroenterol"},{"key":"12761_CR3","doi-asserted-by":"publisher","first-page":"17036","DOI":"10.1038\/nrdp.2017.36","volume":"3","author":"JA Ajani","year":"2017","unstructured":"Ajani JA, et al. Gastric adenocarcinoma. Nat Rev Dis Primers. 2017;3:17036.","journal-title":"Nat Rev Dis Primers"},{"issue":"9","key":"12761_CR4","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1245\/s10434-017-5838-y","volume":"24","author":"N Ikoma","year":"2017","unstructured":"Ikoma N, et al. Patterns of initial recurrence in gastric adenocarcinoma in the era of preoperative therapy. Ann Surg Oncol. 2017;24(9):2679\u201387.","journal-title":"Ann Surg Oncol"},{"issue":"4_suppl","key":"12761_CR5","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1200\/JCO.2020.38.4_suppl.327","volume":"38","author":"MI Meneses Medina","year":"2020","unstructured":"Meneses Medina MI, et al. Morbidity associated to advanced gastric cancer and its impact on overall survival. J Clin Oncol. 2020;38(4_suppl):327\u2013327.","journal-title":"J Clin Oncol"},{"issue":"6","key":"12761_CR6","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.surg.2013.01.001","volume":"153","author":"HR Alexander Jr","year":"2013","unstructured":"Alexander HR Jr, et al. Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery. 2013;153(6):779\u201386.","journal-title":"Surgery"},{"issue":"1","key":"12761_CR7","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1056\/NEJMoa052985","volume":"354","author":"DK Armstrong","year":"2006","unstructured":"Armstrong DK, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34\u201343.","journal-title":"N Engl J Med"},{"issue":"20","key":"12761_CR8","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1200\/JCO.2011.39.7166","volume":"30","author":"TC Chua","year":"2012","unstructured":"Chua TC, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30(20):2449\u201356.","journal-title":"J Clin Oncol"},{"issue":"1","key":"12761_CR9","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1245\/s10434-020-08739-5","volume":"28","author":"B Badgwell","year":"2021","unstructured":"Badgwell B, et al. A phase II trial of cytoreduction, gastrectomy, and hyperthermic intraperitoneal perfusion with chemotherapy for patients with gastric cancer and carcinomatosis or positive cytology. Ann Surg Oncol. 2021;28(1):258\u201364.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"12761_CR10","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/jso.23633","volume":"110","author":"U Rudloff","year":"2014","unstructured":"Rudloff U, et al. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial. J Surg Oncol. 2014;110(3):275\u201384.","journal-title":"J Surg Oncol"},{"issue":"13","key":"12761_CR11","doi-asserted-by":"publisher","first-page":"9060","DOI":"10.1245\/s10434-021-10157-0","volume":"28","author":"L Marano","year":"2021","unstructured":"Marano L, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for gastric cancer with synchronous peritoneal metastases: multicenter Study of \u2018Italian peritoneal surface malignancies oncoteam-S.I.C.O.\u2019 Ann Surg Oncol. 2021;28(13):9060\u201370.","journal-title":"Ann Surg Oncol"},{"issue":"23","key":"12761_CR12","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1200\/JCO.18.01688","volume":"37","author":"PE Bonnot","year":"2019","unstructured":"Bonnot PE, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis. J Clin Oncol. 2019;37(23):2028\u201340.","journal-title":"J Clin Oncol"},{"issue":"1","key":"12761_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s10120-019-00978-0","volume":"23","author":"B Rau","year":"2020","unstructured":"Rau B, et al. Peritoneal metastasis in gastric cancer: results from the German database. Gastric Cancer. 2020;23(1):11\u201322.","journal-title":"Gastric Cancer"},{"issue":"6","key":"12761_CR14","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.21037\/jgo.2017.09.01","volume":"8","author":"ZJ Brown","year":"2017","unstructured":"Brown ZJ, et al. Heated intraperitoneal chemotherapy and gastrectomy for gastric cancer in the U.S.: the time is now. J Gastrointest Oncol. 2017;8(6):1109\u201313.","journal-title":"J Gastrointest Oncol"},{"issue":"11","key":"12761_CR15","doi-asserted-by":"publisher","first-page":"3338","DOI":"10.1245\/s10434-017-6047-4","volume":"24","author":"B Badgwell","year":"2017","unstructured":"Badgwell B, et al. Phase II trial of laparoscopic hyperthermic intraperitoneal chemoperfusion for peritoneal carcinomatosis or positive peritoneal cytology in patients with gastric adenocarcinoma. Ann Surg Oncol. 2017;24(11):3338\u201344.","journal-title":"Ann Surg Oncol"},{"issue":"13","key":"12761_CR16","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.1245\/s10434-020-08968-8","volume":"27","author":"AN Blumenthaler","year":"2020","unstructured":"Blumenthaler AN, et al. Laparoscopic HIPEC for low-volume peritoneal metastasis in gastric and gastroesophageal adenocarcinoma. Ann Surg Oncol. 2020;27(13):5047\u201356.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"12761_CR17","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1007\/s00464-017-5668-9","volume":"32","author":"B Badgwell","year":"2018","unstructured":"Badgwell B, et al. Lessons learned from a phase II clinical trial of laparoscopic HIPEC for gastric cancer. Surg Endosc. 2018;32(1):512.","journal-title":"Surg Endosc"},{"issue":"5","key":"12761_CR18","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1245\/s10434-018-07140-7","volume":"26","author":"TE Newhook","year":"2019","unstructured":"Newhook TE, et al. Laparoscopic hyperthermic intraperitoneal chemotherapy is safe for patients with peritoneal metastases from gastric cancer and may lead to gastrectomy. Ann Surg Oncol. 2019;26(5):1394\u2013400.","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"12761_CR19","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1245\/s10434-019-07450-4","volume":"26","author":"I Manzanedo","year":"2019","unstructured":"Manzanedo I, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for gastric cancer with peritoneal carcinomatosis: multicenter study of Spanish group of peritoneal oncologic surgery (GECOP). Ann Surg Oncol. 2019;26(8):2615\u201321.","journal-title":"Ann Surg Oncol"},{"key":"12761_CR20","doi-asserted-by":"publisher","first-page":"S1040","DOI":"10.1016\/j.annonc.2021.08.1485","volume":"32","author":"B Rau","year":"2021","unstructured":"Rau B, et al. 1376O The effect of hyperthermic intraperitoneal chemotherapy (HIPEC) upon cytoreductive surgery (CRS) in gastric cancer (GC) with synchronous peritoneal metastasis (PM): a randomized multicentre phase III trial (GASTRIPEC-I-trial). Ann Oncol. 2021;32:S1040.","journal-title":"Ann Oncol"},{"issue":"12","key":"12761_CR21","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.1245\/s10434-010-1183-0","volume":"17","author":"JJ Mezhir","year":"2010","unstructured":"Mezhir JJ, et al. Positive peritoneal cytology in patients with gastric cancer: natural history and outcome of 291 patients. Ann Surg Oncol. 2010;17(12):3173\u201380.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"12761_CR22","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s10120-017-0749-y","volume":"21","author":"S Jamel","year":"2018","unstructured":"Jamel S, et al. Prognostic significance of peritoneal lavage cytology in staging gastric cancer: systematic review and meta-analysis. Gastric Cancer. 2018;21(1):10\u20138.","journal-title":"Gastric Cancer"},{"issue":"10184","key":"12761_CR23","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"S-E Al-Batran","year":"2019","unstructured":"Al-Batran S-E, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet. 2019;393(10184):1948\u201357.","journal-title":"Lancet"},{"key":"12761_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s12029-021-00698-8","author":"F Tidadini","year":"2021","unstructured":"Tidadini F, et al. Effect of pressurized intraperitoneal aerosol chemotherapy on the survival rate of patients with peritoneal carcinomatosis of gastric origin. J Gastrointest Cancer. 2022. https:\/\/doi.org\/10.1007\/s12029-021-00698-8.","journal-title":"J Gastrointest Cancer"},{"issue":"19","key":"12761_CR25","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1200\/JCO.2018.77.8613","volume":"36","author":"H Ishigami","year":"2018","unstructured":"Ishigami H, et al. Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial. J Clin Oncol. 2018;36(19):1922\u20139.","journal-title":"J Clin Oncol"},{"issue":"7","key":"12761_CR26","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1245\/s10434-018-6471-0","volume":"25","author":"N Ikoma","year":"2018","unstructured":"Ikoma N, et al. Nodal downstaging in gastric cancer patients: promising survival if ypN0 is achieved. Ann Surg Oncol. 2018;25(7):2012\u20137.","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"12761_CR27","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1016\/j.ejso.2018.06.036","volume":"44","author":"C Rihuete Caro","year":"2018","unstructured":"Rihuete Caro C, et al. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with gastric cancer and peritoneal carcinomatosis. Eur J Surg Oncol. 2018;44(11):1805\u201310.","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"12761_CR28","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41591-020-1125-8","volume":"27","author":"R Wang","year":"2021","unstructured":"Wang R, et al. Single-cell dissection of intratumoral heterogeneity and lineage diversity in metastatic gastric adenocarcinoma. Nat Med. 2021;27(1):141\u201351.","journal-title":"Nat Med"},{"issue":"1","key":"12761_CR29","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1158\/2159-8290.CD-17-0395","volume":"8","author":"E Pectasides","year":"2018","unstructured":"Pectasides E, et al. Genomic heterogeneity as a barrier to precision medicine in gastroesophageal adenocarcinoma. Cancer Discov. 2018;8(1):37\u201348.","journal-title":"Cancer Discov"},{"issue":"1","key":"12761_CR30","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1186\/s12885-021-08872-8","volume":"21","author":"TO Gotze","year":"2021","unstructured":"Gotze TO, et al. Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II\/III adenocarcinoma: the phase III \u201cPREVENT\u201d- (FLOT9) trial of the AIO \/CAOGI \/ACO. BMC Cancer. 2021;21(1):1158.","journal-title":"BMC Cancer"},{"key":"12761_CR31","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/1471-2407-14-183","volume":"14","author":"O Glehen","year":"2014","unstructured":"Glehen O, et al. GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicenter phase III study. BMC Cancer. 2014;14:183.","journal-title":"BMC Cancer"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-12761-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-022-12761-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-12761-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T21:32:47Z","timestamp":1675891967000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-022-12761-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,8]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["12761"],"URL":"https:\/\/doi.org\/10.1245\/s10434-022-12761-0","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,8]]},"assertion":[{"value":"8 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Alisa Blumenthaler participated in a T32 research fellowship funded by the NIH from July 2019\u2013June 2021, including work on this manuscript. The funder did not have any influence over the work included in this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}